{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:28:21Z","timestamp":1793968101675,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473764"],"award-info":[{"award-number":["82473764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119410","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:59:23Z","timestamp":1791561563000},"page":"119410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Discovery of new 7-azaindole derivatives as CSN5 inhibitors with in vitro antitumor activity against triple-negative breast cancer"],"prefix":"10.1016","volume":"321","author":[{"given":"Zhiwen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiting","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8397-8079","authenticated-orcid":false,"given":"Lingling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-1181","authenticated-orcid":false,"given":"Hua-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119410_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119410_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s11658-025-00789-5","article-title":"Programmed cell death in triple-negative breast cancer","volume":"30","author":"Liu","year":"2025","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejmech.2026.119410_bib3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12032-025-03066-9","article-title":"Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions","volume":"42","author":"Sood","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.119410_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2527303","article-title":"Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy","volume":"14","author":"Gbadamosi","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejmech.2026.119410_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2026.119410_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119410_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119410_bib8","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119410_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.tibs.2022.08.003","article-title":"The COP9 signalosome: a versatile regulatory hub of Cullin-RING ligases","volume":"48","author":"Schulze-Niemand","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.119410_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.20892\/j.issn.2095-3941.2021.0605","article-title":"Targeting the COP9 signalosome for cancer therapy","volume":"19","author":"Du","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119410_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183761","article-title":"Jab1 promotes immune evasion and progression in acute myeloid leukemia models under oxidative stress","volume":"135","author":"Zhang","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119410_bib12","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1111\/jcmm.16334","article-title":"Prognostic role of c-Jun activation domain-binding protein-1 in cancer: a systematic review and meta-analysis","volume":"25","author":"Shi","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119410_bib13","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.7150\/ijbs.60594","article-title":"SENP1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation","volume":"18","author":"Gao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119410_bib14","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr2902","article-title":"Stat3 and CCAAT\/enhancer binding protein beta (C\/EBP-beta) regulate Jab1\/CSN5 expression in mammary carcinoma cells","volume":"13","author":"Shackleford","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119410_bib15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41418-025-01642-0","article-title":"JAB1\/CRL4B complex represses PPARG\/ACSL5 expression to promote breast tumorigenesis","volume":"33","author":"Hu","year":"2026","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119410_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12553","article-title":"Pan-cancer analyses of Jab1\/COPS5 reveal oncogenic role and clinical outcome in human cancer","volume":"8","author":"Wang","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2026.119410_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12964-022-00934-z","article-title":"Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3\/Jab1-PD-L1 signalling","volume":"20","author":"Zhu","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2026.119410_bib18","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1016\/j.febslet.2010.10.039","article-title":"CSN5\/Jab1 controls multiple events in the mammalian cell cycle","volume":"584","author":"Yoshida","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2026.119410_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12943-025-02422-7","article-title":"Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer","volume":"24","author":"Peng","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119410_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41388-021-02118-4","article-title":"Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer","volume":"41","author":"Mazzu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119410_bib21","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-16-2426","article-title":"Jab1\/Csn5-Thioredoxin signaling in relapsed acute monocytic leukemia under oxidative stress","volume":"23","author":"Zhou","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119410_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111876","article-title":"CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein","volume":"388","author":"Huang","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2026.119410_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2019.08.016","article-title":"MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1\/CSN5 in triple-negative breast cancer","volume":"465","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119410_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cellsig.2018.09.010","article-title":"Jab1\/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51","volume":"53","author":"Liu","year":"2019","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2026.119410_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.7150\/ijbs.89700","article-title":"A novel CSN5\/CRT O-GlcNAc\/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer","volume":"20","author":"Yan","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119410_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13166","article-title":"Targeted inhibition of the COP9 signalosome for treatment of cancer","volume":"7","author":"Schlierf","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119410_bib27","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/anie.201608672","article-title":"Azaindoles as zinc-binding small-molecule inhibitors of the JAMM protease CSN5","volume":"56","author":"Altmann","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119410_bib28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.apsb.2020.06.014","article-title":"Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119410_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.pan.2021.01.023","article-title":"Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-\u03baB\/STAT3 and NF-\u03baB\/CSN5 signaling pathways","volume":"21","author":"Ruan","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejmech.2026.119410_bib30","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1021\/acs.jmedchem.4c01514","article-title":"Discovering new metallo-deubiquitinase CSN5 inhibitors by a non-catalytic activity assay platform","volume":"67","author":"Yan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119410_bib31","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1021\/acs.jmedchem.5c00184","article-title":"Discovery of new azaindole metallo-deubiquitinase CSN5 inhibitors","volume":"68","author":"Lei","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119410_bib32","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/acs.jmedchem.5c02669","article-title":"A novel CSN5 inhibitor drives tumor-intrinsic PD-L1 degradation and exerts direct antitumor efficacy in triple-negative breast cancer","volume":"69","author":"Wang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119410_bib33","article-title":"Adaptive exchange sustains cullin-RING ubiquitin ligase networks and proper licensing of DNA replication","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119410_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cellsig.2017.02.013","article-title":"CSN5\/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells","volume":"34","author":"Jumpertz","year":"2017","journal-title":"Cell. Signal"},{"key":"10.1016\/j.ejmech.2026.119410_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2018.03.183","article-title":"CSN5\/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin","volume":"500","author":"Li","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119410_bib36","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa206","article-title":"CSN5 promotes carcinogenesis of thyroid carcinoma cells through ANGPTL2","volume":"162","author":"Xie","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2026.119410_bib37","article-title":"Berberine derivative B68 promotes tumor immune clearance by dual-targeting BMI1 for senescence induction and CSN5 for PD-L1 degradation","volume":"12","author":"Hu","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119410_bib38","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2174\/1871520619666190725122400","article-title":"Jab1-siRNA induces cell growth inhibition and cell cycle arrest in gall bladder cancer cells via targeting Jab1 signalosome","volume":"19","author":"Pandey","year":"2019","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119410_bib39","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1038\/onc.2012.294","article-title":"Suppression of Jab1\/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways","volume":"32","author":"Pan","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119410_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/cbt.27823","article-title":"Emerging roles of Jab1\/CSN5 in DNA damage response, DNA repair, and cancer","volume":"15","author":"Pan","year":"2014","journal-title":"Cancer Biol. Ther."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600855X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600855X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:56:59Z","timestamp":1793966219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600855X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":40,"alternative-id":["S022352342600855X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119410","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of new 7-azaindole derivatives as CSN5 inhibitors with in vitro antitumor activity against triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119410"}}